Researchers studying the molecular landscape of over 500 patients with relapsed or refractory multiple myeloma discovered a prevalence of activated key oncogenic pathways in these patients—much more than previously thought. Upward of 45% to 65% of NF-κB and RAS/MAPK pathways each had alterations. The study was published by Vo et al in Nature Communications.
Further, senior study author Arul Chinnaiyan, MD, PhD, Director of the Michigan Center for Translational Pathology, and his team found a link between mutations and RASopathies, a certain group of genetic syndromes, in patients with relapsed treatment-resistant multiple myeloma. This was the first observation of its kind.
The team compared the molecular makeup of patients with untreated multiple myeloma to those with the relapsed treatment-resistant version of the disease. Comparing these patients allowed researchers to describe drivers of the more aggressive type of multiple myeloma.
“It also led us to discover resistance mechanisms that occur in the patients whose disease relapses and is resistant to treatment,” Dr. Chinnaiyan said. “We found that an upwards of a quarter of the patients had developed some sort of resistance mechanism. The genetic alterations that occur in these patients make them resistant to commonly used treatments of multiple myeloma.”
This study was funded by the Multiple Myeloma Research Foundation (MMRF) and included patient samples from its Multiple Myeloma Research Consortium (MMRC)—a collaborative network of 22 leading cancer centers focused on investigating the most promising early-stage therapies. Clinical sequencing is powered by the Mi-Oncoseq Program at Michigan Medicine, directed by Dr. Chinnaiyan and Dan Robinson, PhD. From knowledge gained through this work, researchers have initiated a study that assigns patients to individual arms of a clinical trial based on their molecular profile to match alterations with potential therapies using a comprehensive sequencing-based approach.
Dr. Chinnaiyan said that while this current study was retrospective, he’s hopeful about the future. “We’re developing tools and knowledge to translate these strategies into actual clinical impact for patients.”
“Treatment of relapsed multiple myeloma can be extremely difficult despite the tremendous progress we have made,” said Hearn Jay Cho, MD, PhD, Chief Medical Officer of the MMRF. “Uncovering new targets and therapies that act upon them may be helpful in the future for patients who develop resistance to current treatment such as CD38-targeting monoclonal antibodies....”
Disclosure: For full disclosures of the study authors, visit nature.com.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.